Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kestra Medical Technologies (KMTS) Cost of Revenue (2024 - 2026)

Kestra Medical Technologies (KMTS) has disclosed Cost of Revenue for 2 consecutive years, with $11.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 25.46% to $11.1 million in Q4 2025 year-over-year; TTM through Oct 2025 was $39.8 million, a N/A change, with the full-year FY2025 number at $35.6 million, up 29.7% from a year prior.
  • Cost of Revenue was $11.1 million for Q4 2025 at Kestra Medical Technologies, up from $10.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $11.1 million in Q4 2025 to a low of $7.4 million in Q1 2024.